892414-47-0

Basic information

• Product Name: 3-Trifluoromethyl-1H-pyrrolo[2,3-b]pyridine
• Synonyms: 3-Trifluoromethyl-1H-pyrrolo[2,3-b]pyridine;3--trifluoromethyl-7-azaindole;3-(trifluoroMethyl)-1H-pyrrolo[2,3;3-Trifluoromethyl-1H-pyrrolo[2,3-b]pyridine-4;3-(Trifluoromethyl)-1H-pyrrolo[2,3-b]
• CAS NO: 892414-47-0
• Molecular Formula: C₈H₅F₃N₂
• Molecular Weight: 186.1339096
• Product Categories: Non-Chiral heterocyclic compounds
• Mol File: 892414-47-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 1.447±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: 2-8°C
• PKA: 12.04±0.40(Predicted)
• CAS DataBase Reference: 3-Trifluoromethyl-1H-pyrrolo[2,3-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Trifluoromethyl-1H-pyrrolo[2,3-b]pyridine(892414-47-0)
• EPA Substance Registry System: 3-Trifluoromethyl-1H-pyrrolo[2,3-b]pyridine(892414-47-0)

Safety Data

• Hazardous Substances Data: 892414-47-0(Hazardous Substances Data)

Usage

General Description

3-Trifluoromethyl-1H-pyrrolo[2,3-b]pyridine is a chemical compound with the molecular formula C8H5F3N2. It belongs to the class of pyrrolopyridine compounds and consists of a pyrrole ring fused with a pyridine ring. The addition of a trifluoromethyl group to the pyrrolopyridine structure imparts unique chemical and physical properties to the compound. It is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. Additionally, its unique structure and properties make it a valuable tool in medicinal chemistry research for the development of new drugs. 3-Trifluoromethyl-1H-pyrrolo[2,3-b]pyridine may also have potential applications in other industries such as materials science and catalysis.

Upstream product

• 892414-46-9 3-(trifluoromethyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-3-ol 
• 932406-33-2 2,2,2-trifluoro-1-(2-fluoropyridin-3-yl)ethane-1,1-diol 
• 892414-45-8 1,1,1-trifluoro-2-(2-fluoropyridin-3-yl)-3-nitropropan-2-ol 
• 372-48-5 2-fluoropyridine 
• 271-63-6 7-Azaindole 
• 1961266-44-3 2,8-difluoro-5-(trifluoromethyl)-5H-dibenzo[b,d]thiophen-5-ium trifluoromethanesulfonate 

Downstream Products

• 892414-50-5 6-chloro-4-nitro-3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine 
• 892414-51-6 6-chloro-4-nitro-3-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridine 
• 892414-55-0 4-[(6-chloro-3-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]-pyridin-4-yl)oxy]-3,5-difluoroaniline 
• 932406-43-4 benzyl (6-chloro-3-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)(2-fluoro-4-nitrophenyl)acetate 
• 1342811-50-0 C₁₅H₈BrF₃N₂O 
• 1150618-36-2 5-bromo-3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine 
• 1620574-99-3 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

Nickel(IV)-Catalyzed C-H Trifluoromethylation of (Hetero)arenes

This Article describes the development of a stable NiIV complex that mediates C(sp2)-H trifluoromethylation reactions. This reactivity is first demonstrated stoichiometrically and then successfully translated to a NiIV-catalyzed C-H trifluoromethylation of electron-rich arene and heteroarene substrates. Both experimental and computational mechanistic studies support a radical chain pathway involving NiIV, NiIII, and NiII intermediates.

3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS

The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.

Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins

The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.